Skip to Content

Join the 'Gamunex' group to help and get support from people like you.

Gamunex News

Densensitization Procedure Helps Hard-to-Match Kidney Recipients

Posted 27 Jul 2011 by Drugs.com

WEDNESDAY, July 27 – A combination therapy that "desensitizes" kidney transplant recipients could help hard-to-match patients find a needed kidney faster. The desensitization procedure combines the use of plasmapheresis – a machine that filters the blood plasma to remove antibodies – and low-doses of a medication called intravenous immune globulin (IVIG). The combination of these therapies improves survival rates dramatically. Eight years after receiving a transplant, survival rates were 81 percent for those who received the treatment compared to just 31 percent for people who had to stay on dialysis, new research found. "This is a huge unmet problem. There are probably as many as 30,000 people who have been exposed to foreign tissue waiting for a kidney. They're really hard to match," explained study author Dr. Robert Montgomery, director of the comprehensive transplant program at ... Read more

Related support groups: Renal Transplant, Gammagard, Gamunex, Privigen, Immune Globulin Intravenous, Sandoglobulin, Carimune, Iveegam En, Gamimune, Panglobulin, Gamimune N 5%, Gammaplex, Polygam S/D, Gammagard S/D, Flebogamma, Venoglobulin-S 5%, Octagam, Gamimune N 10%, Panglobulin NF, Gammar-P IV

Talecris Biotherapeutics Receives FDA Approval for Gamunex-C

Posted 17 Oct 2010 by Drugs.com

RESEARCH TRIANGLE PARK , N.C., Oct. 14 /PRNewswire-FirstCall/ – Talecris Biotherapeutics (Nasdaq: TLCR) announced today that the U.S. Food and Drug Administration (FDA) approved Gamunex-C (Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified) for subcutaneous administration in the treatment of primary immunodeficiency (PI). The newly approved Gamunex-C provides both the intravenous route of administration and a new subcutaneous route of administration. The intravenous delivery mode is approved to treat PI, chronic inflammatory demyelinating polyneuropathy (CIDP), and idiopathic thrombocytopenic purpura (ITP). The subcutaneous mode is approved to treat only PI. The difference between Gamunex and Gamunex-C is the labeling and packaging information. Gamunex-C labeling describes both the intravenous and subcutaneous routes of administration, whereas Gamunex labeling ... Read more

Related support groups: Primary Immunodeficiency Syndrome, Gamunex, Immune Globulin Subcutaneous

Ask a Question

Further Information

Related Condition Support Groups

Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Idiopathic (Immune) Thrombocytopenic Purpura, Primary Immunodeficiency Syndrome, Evan's Syndrome

Gamunex Patient Information at Drugs.com